Stimulate the generation of myelin, a therapy for the CHARGE Syndrome?

CHARGE syndrome is a rare genetic disease (1/10 000 births) caused by mutation of a copy of CHD7 gene resulting in many defects. This syndrome is particularly recognized as the major cause of deafness and congenital blindness. In affected children, neurological disorders increase with age. The team of Dr. Parras to the ICM has shown that this anomaly would be linked to a deficient myelination. Their findings indicate that CHD7 gene is essential for the maturation of oligodendrocytes and myelin formation. This new potential therapeutic target could help develop new treatments for people suffering from diseases due to defects in myelination.



Live with Parkinson's disease

New book is for PD patients, their families, but also the general public, containing medical and scientific reminders released last month in bookstores! Dr Bashir Jarraya researcher NeuroSpin @CEA Saclay, neurosurgeon at the Foch Hospital and University Professor at Versailles is co-author with Dr. Hausser-Hauw and Dr. Bourdain of Foch Hospital.


Regulators neurons sleep-wake rhythms involved in Parkinson's disease

A new discovery from the team of Pr. Etienne C.Hirsch at the ICM highlights the protective role of new neurons in Parkinson's disease. This study suggests a promising new therapeutic approach for this disease.


April 11th : World Parkinson's disease day

In the context of World Parkinson’s disease day on April 11th, the ICM focuses on the latest discoveries.

Parkinson’s disease is the most common neurodegenerative disease after Alzheimer’s. Second cause of motor disability with 4 million people in the world, Parkinson’s disease is characterised by the death of a population of neurons, called dopaminergic. These neurons produce a substance, dopamine, playing a role in the transmission of information between neurons, and essential to the harmonious control of movements. Symptoms include slow movements, stiffness of the limbs and chest, tremor, and walking ability disorders. These motor symptoms can lead to disability and loss of total autonomy in the person suffering from this disease.

Drug treatments can reduce the symptoms of the disease, by using dopamine agonists. However, there is no treatment to slow the progression of the disease; we can’t prevent neuronal death. Moreover, this neuronal degeneration is unfortunately not limited to dopaminergic neurons, nor to the motor system.

What are the risk factors of the disease ? What are the mechanisms responsible for the loss of neurons ? And how to counter them in order to slow the progression of the disease ? Researchers and clinicians take advantage of the ICM premises and its cutting-edge technology platforms to answer these questions and fight the disease.